US researchers uncovered a link between the use of GLP-1 agonists - such as Ozempic, Wegovy, Mounjaro, and Zepbound - and a reduced likelihood of being diagnosed with several types of cancer. The study analysed a decade's worth of medical data, comparing over 43,000 users of GLP-1 medications with a matched group of non-users. All participants in the study were considered at risk for obesity-related cancers. – Reuters (25 Augst 2025)
The study, published in the journal JAMA Oncology, revealed that after adjusting for individual risk factors, people taking GLP-1 drugs had an overall cancer risk that was 17% lower than those not taking the medication.
“Researchers cannot definitively say whether the reduced cancer risk is a direct result of the GLP-1 medications themselves or an indirect benefit of the significant weight loss these drugs induce.
“While the overall picture was positive, the study did associate GLP-1 drugs with a slight increase in the risk for kidney cancer.”